Allogeneic hematopoietic stem cell transplantation for elderly patients

Allogeneic hematopoietic stem cell transplantation for elderly patients - Allo-HSCT for elderly patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017744

Enrollment

Registered

2015-05-30

Start date

2009-02-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic malignancy

Interventions

Allogeneic hematopoietic stem cell transplantation was underwent with the below conditioning regimen. (1) Fludarabine 30 mg/m2 x 5 days + Melphalan (80-140) mg/m2 x 1 day +- TBI 2Gy x 2 or (2) Flud

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. For hematologic malignancies, indication for transplantation is equivalent to normal procedures. 2. Patient age 60-75 yo. 3. Written informed consent was achieved.

Exclusion criteria

Exclusion criteria: (1) Presence of other lethal complications. (2) Severe heart disease (ejection fraction < 40 %, uncontrollable arrhythmia or hypertension). (3) Severe kidney dysfunction (CCr < 30 ml/min). (4) Severe respiratory diease (PaO2 < 70 mmHg, DLCO < 50% or FEV1.0 < 60 %). (5) Severe liver dysfunction (T.Bil > 2.5 mg/dl, cirrhosis). (6) Cases considered to be not suitable in the conference of our department.

Design outcomes

Primary

Measure	Time frame
survival at day 100 after trasnplantation	—

Secondary

Measure	Time frame
Cumulative incidence of acute and chronic graft-versus-host disease. Disease free and overall survival at 1 year after transplantation	—

Countries

Japan

Contacts

Public ContactAkira Honda

Univesity of Tokyo Hospital Hematology and Oncology

ahonda-spr@umin.org03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026